PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in Colorectal cancer

Fiona L. Day, Robert Jorissen, Lara Lipton, Dmitri Mouradov, Anuratha Sakthianandeswaren, Michael Christie, Shan Li, Cary Tsui, Jeannie Tie, Jayesh Desai, Zheng Zhou Xu, Peter Molloy, Vicki Whitehall, Barbara A. Leggett, Ian T. Jones, Stephen McLaughlin, Robyn L. Ward, Nicholas J. Hawkins, Andrew R. Ruszkiewicz, James Moore & 5 others Dana Busam, Qi Zhao, Robert L. Strausberg, Peter Gibbs, Oliver M. Sieber

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Purpose: PIK3CA and PTEN mutations are prevalent in colorectal cancer and potential markers of response to mitogen-activated protein/extracellular signal-regulated kinase inhibitors and anti-EGF receptor antibody therapy. Relationships between phosphoinositide 3-kinase (PI3K) pathway mutation, clinicopathologic characteristics, molecular features, and prognosis remain controversial. Experimental Design: A total of 1,093 stage I-IV colorectal cancers were screened for PIK3CA (exons 9 and 20), KRAS (codons 12-13), BRAF (codon 600) mutations, and microsatellite instability (MSI). PTEN (exons 3-8) and CpG island methylator phenotype (CIMP) status were determined in 744 and 489 cases. PIK3CA data were integrated with 17 previous reports (n = 5,594). Results: PIK3CA and PTEN mutations were identified in 11.9% and 5.8% of colorectal cancers. PTEN mutation was associated with proximal tumors, mucinous histology, MSI-high (MSI-H), CIMP-high (CIMPH), and BRAF mutation (P < 0.02). PIK3CA mutation was related to older age, proximal tumors, mucinous histology, and KRAS mutation (P < 0.04). In integrated cohort analysis, PIK3CA exon 9 and 20 mutations were overrepresented in proximal, CIMP-low (CIMP-L), and KRAS-mutated cancers (P ≤ 0.011). Comparing PIK3CA exonic mutants, exon 20 mutation was associated with MSI-H, CIMP-H, and BRAF mutation, and exon 9 mutation was associated with KRAS mutation (P ≤ 0.027). Disease-free survival for stage II/III colorectal cancers did not differ by PI3K pathway status. Conclusion: PI3K pathway mutation is prominent in proximal colon cancers, with PIK3CA exon 20 and PTEN mutations associated with features of the sessile-serrated pathway (MSI-H/CIMP-H/BRAFmut), and PIK3CA exon 9 (and to a lesser extent exon 20) mutation associated with features of the traditional serrated pathway (CIMP-L/KRASmut) of tumorigenesis. Our data highlight the PI3K pathway as a therapeutic target in distinct colorectal cancer subtypes.

LanguageEnglish
Pages3285-3296
Number of pages12
JournalClinical Cancer Research
Volume19
Issue number12
DOIs
Publication statusPublished - 15 Jun 2013

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Day, Fiona L. ; Jorissen, Robert ; Lipton, Lara ; Mouradov, Dmitri ; Sakthianandeswaren, Anuratha ; Christie, Michael ; Li, Shan ; Tsui, Cary ; Tie, Jeannie ; Desai, Jayesh ; Xu, Zheng Zhou ; Molloy, Peter ; Whitehall, Vicki ; Leggett, Barbara A. ; Jones, Ian T. ; McLaughlin, Stephen ; Ward, Robyn L. ; Hawkins, Nicholas J. ; Ruszkiewicz, Andrew R. ; Moore, James ; Busam, Dana ; Zhao, Qi ; Strausberg, Robert L. ; Gibbs, Peter ; Sieber, Oliver M. / PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in Colorectal cancer. In: Clinical Cancer Research. 2013 ; Vol. 19, No. 12. pp. 3285-3296.
@article{7216ea3ab2414be48977b8b793628b07,
title = "PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in Colorectal cancer",
abstract = "Purpose: PIK3CA and PTEN mutations are prevalent in colorectal cancer and potential markers of response to mitogen-activated protein/extracellular signal-regulated kinase inhibitors and anti-EGF receptor antibody therapy. Relationships between phosphoinositide 3-kinase (PI3K) pathway mutation, clinicopathologic characteristics, molecular features, and prognosis remain controversial. Experimental Design: A total of 1,093 stage I-IV colorectal cancers were screened for PIK3CA (exons 9 and 20), KRAS (codons 12-13), BRAF (codon 600) mutations, and microsatellite instability (MSI). PTEN (exons 3-8) and CpG island methylator phenotype (CIMP) status were determined in 744 and 489 cases. PIK3CA data were integrated with 17 previous reports (n = 5,594). Results: PIK3CA and PTEN mutations were identified in 11.9{\%} and 5.8{\%} of colorectal cancers. PTEN mutation was associated with proximal tumors, mucinous histology, MSI-high (MSI-H), CIMP-high (CIMPH), and BRAF mutation (P < 0.02). PIK3CA mutation was related to older age, proximal tumors, mucinous histology, and KRAS mutation (P < 0.04). In integrated cohort analysis, PIK3CA exon 9 and 20 mutations were overrepresented in proximal, CIMP-low (CIMP-L), and KRAS-mutated cancers (P ≤ 0.011). Comparing PIK3CA exonic mutants, exon 20 mutation was associated with MSI-H, CIMP-H, and BRAF mutation, and exon 9 mutation was associated with KRAS mutation (P ≤ 0.027). Disease-free survival for stage II/III colorectal cancers did not differ by PI3K pathway status. Conclusion: PI3K pathway mutation is prominent in proximal colon cancers, with PIK3CA exon 20 and PTEN mutations associated with features of the sessile-serrated pathway (MSI-H/CIMP-H/BRAFmut), and PIK3CA exon 9 (and to a lesser extent exon 20) mutation associated with features of the traditional serrated pathway (CIMP-L/KRASmut) of tumorigenesis. Our data highlight the PI3K pathway as a therapeutic target in distinct colorectal cancer subtypes.",
author = "Day, {Fiona L.} and Robert Jorissen and Lara Lipton and Dmitri Mouradov and Anuratha Sakthianandeswaren and Michael Christie and Shan Li and Cary Tsui and Jeannie Tie and Jayesh Desai and Xu, {Zheng Zhou} and Peter Molloy and Vicki Whitehall and Leggett, {Barbara A.} and Jones, {Ian T.} and Stephen McLaughlin and Ward, {Robyn L.} and Hawkins, {Nicholas J.} and Ruszkiewicz, {Andrew R.} and James Moore and Dana Busam and Qi Zhao and Strausberg, {Robert L.} and Peter Gibbs and Sieber, {Oliver M.}",
year = "2013",
month = "6",
day = "15",
doi = "10.1158/1078-0432.CCR-12-3614",
language = "English",
volume = "19",
pages = "3285--3296",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

Day, FL, Jorissen, R, Lipton, L, Mouradov, D, Sakthianandeswaren, A, Christie, M, Li, S, Tsui, C, Tie, J, Desai, J, Xu, ZZ, Molloy, P, Whitehall, V, Leggett, BA, Jones, IT, McLaughlin, S, Ward, RL, Hawkins, NJ, Ruszkiewicz, AR, Moore, J, Busam, D, Zhao, Q, Strausberg, RL, Gibbs, P & Sieber, OM 2013, 'PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in Colorectal cancer', Clinical Cancer Research, vol. 19, no. 12, pp. 3285-3296. https://doi.org/10.1158/1078-0432.CCR-12-3614

PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in Colorectal cancer. / Day, Fiona L.; Jorissen, Robert; Lipton, Lara; Mouradov, Dmitri; Sakthianandeswaren, Anuratha; Christie, Michael; Li, Shan; Tsui, Cary; Tie, Jeannie; Desai, Jayesh; Xu, Zheng Zhou; Molloy, Peter; Whitehall, Vicki; Leggett, Barbara A.; Jones, Ian T.; McLaughlin, Stephen; Ward, Robyn L.; Hawkins, Nicholas J.; Ruszkiewicz, Andrew R.; Moore, James; Busam, Dana; Zhao, Qi; Strausberg, Robert L.; Gibbs, Peter; Sieber, Oliver M.

In: Clinical Cancer Research, Vol. 19, No. 12, 15.06.2013, p. 3285-3296.

Research output: Contribution to journalArticle

TY - JOUR

T1 - PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in Colorectal cancer

AU - Day, Fiona L.

AU - Jorissen, Robert

AU - Lipton, Lara

AU - Mouradov, Dmitri

AU - Sakthianandeswaren, Anuratha

AU - Christie, Michael

AU - Li, Shan

AU - Tsui, Cary

AU - Tie, Jeannie

AU - Desai, Jayesh

AU - Xu, Zheng Zhou

AU - Molloy, Peter

AU - Whitehall, Vicki

AU - Leggett, Barbara A.

AU - Jones, Ian T.

AU - McLaughlin, Stephen

AU - Ward, Robyn L.

AU - Hawkins, Nicholas J.

AU - Ruszkiewicz, Andrew R.

AU - Moore, James

AU - Busam, Dana

AU - Zhao, Qi

AU - Strausberg, Robert L.

AU - Gibbs, Peter

AU - Sieber, Oliver M.

PY - 2013/6/15

Y1 - 2013/6/15

N2 - Purpose: PIK3CA and PTEN mutations are prevalent in colorectal cancer and potential markers of response to mitogen-activated protein/extracellular signal-regulated kinase inhibitors and anti-EGF receptor antibody therapy. Relationships between phosphoinositide 3-kinase (PI3K) pathway mutation, clinicopathologic characteristics, molecular features, and prognosis remain controversial. Experimental Design: A total of 1,093 stage I-IV colorectal cancers were screened for PIK3CA (exons 9 and 20), KRAS (codons 12-13), BRAF (codon 600) mutations, and microsatellite instability (MSI). PTEN (exons 3-8) and CpG island methylator phenotype (CIMP) status were determined in 744 and 489 cases. PIK3CA data were integrated with 17 previous reports (n = 5,594). Results: PIK3CA and PTEN mutations were identified in 11.9% and 5.8% of colorectal cancers. PTEN mutation was associated with proximal tumors, mucinous histology, MSI-high (MSI-H), CIMP-high (CIMPH), and BRAF mutation (P < 0.02). PIK3CA mutation was related to older age, proximal tumors, mucinous histology, and KRAS mutation (P < 0.04). In integrated cohort analysis, PIK3CA exon 9 and 20 mutations were overrepresented in proximal, CIMP-low (CIMP-L), and KRAS-mutated cancers (P ≤ 0.011). Comparing PIK3CA exonic mutants, exon 20 mutation was associated with MSI-H, CIMP-H, and BRAF mutation, and exon 9 mutation was associated with KRAS mutation (P ≤ 0.027). Disease-free survival for stage II/III colorectal cancers did not differ by PI3K pathway status. Conclusion: PI3K pathway mutation is prominent in proximal colon cancers, with PIK3CA exon 20 and PTEN mutations associated with features of the sessile-serrated pathway (MSI-H/CIMP-H/BRAFmut), and PIK3CA exon 9 (and to a lesser extent exon 20) mutation associated with features of the traditional serrated pathway (CIMP-L/KRASmut) of tumorigenesis. Our data highlight the PI3K pathway as a therapeutic target in distinct colorectal cancer subtypes.

AB - Purpose: PIK3CA and PTEN mutations are prevalent in colorectal cancer and potential markers of response to mitogen-activated protein/extracellular signal-regulated kinase inhibitors and anti-EGF receptor antibody therapy. Relationships between phosphoinositide 3-kinase (PI3K) pathway mutation, clinicopathologic characteristics, molecular features, and prognosis remain controversial. Experimental Design: A total of 1,093 stage I-IV colorectal cancers were screened for PIK3CA (exons 9 and 20), KRAS (codons 12-13), BRAF (codon 600) mutations, and microsatellite instability (MSI). PTEN (exons 3-8) and CpG island methylator phenotype (CIMP) status were determined in 744 and 489 cases. PIK3CA data were integrated with 17 previous reports (n = 5,594). Results: PIK3CA and PTEN mutations were identified in 11.9% and 5.8% of colorectal cancers. PTEN mutation was associated with proximal tumors, mucinous histology, MSI-high (MSI-H), CIMP-high (CIMPH), and BRAF mutation (P < 0.02). PIK3CA mutation was related to older age, proximal tumors, mucinous histology, and KRAS mutation (P < 0.04). In integrated cohort analysis, PIK3CA exon 9 and 20 mutations were overrepresented in proximal, CIMP-low (CIMP-L), and KRAS-mutated cancers (P ≤ 0.011). Comparing PIK3CA exonic mutants, exon 20 mutation was associated with MSI-H, CIMP-H, and BRAF mutation, and exon 9 mutation was associated with KRAS mutation (P ≤ 0.027). Disease-free survival for stage II/III colorectal cancers did not differ by PI3K pathway status. Conclusion: PI3K pathway mutation is prominent in proximal colon cancers, with PIK3CA exon 20 and PTEN mutations associated with features of the sessile-serrated pathway (MSI-H/CIMP-H/BRAFmut), and PIK3CA exon 9 (and to a lesser extent exon 20) mutation associated with features of the traditional serrated pathway (CIMP-L/KRASmut) of tumorigenesis. Our data highlight the PI3K pathway as a therapeutic target in distinct colorectal cancer subtypes.

UR - http://www.scopus.com/inward/record.url?scp=84879471604&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-12-3614

DO - 10.1158/1078-0432.CCR-12-3614

M3 - Article

VL - 19

SP - 3285

EP - 3296

JO - Clinical Cancer Research

T2 - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12

ER -